PTK2 and neoplasm: In mice with HGSOC, the combination of FAK inhibitor and anti-TIGIT therapy was able to prolong survival rates, increase the level of CXCL13, which is associated with tumor infiltrating lymphocytes (TLS) formation, and promote B and T-cell enrichment [142].